From methotrexate to pemetrexed and beyond. A review of the pharmacodynamic and clinical properties of antifolates

Walling, Jackie

doi:10.1007/s10637-005-4541-1

Cited by 184Folate and B Vitamins ResearchColorectal Cancer Treatments and StudiesCancer therapeutics and mechanisms

From methotrexate to pemetrexed and beyond. A review of the pharmacodynamic and clinical properties of antifolates

Walling, Jackie·2006·Investigational New Drugs

DOI 10.1007/s10637-005-4541-1

Open this paper in CoChat — free account

Integrity signals

Registry

Crossref · 10.1007/s10637-005-4541-1

Cites

352 of 352 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Aminopterin is the precursor of methotrexate and pemetrexed, folate analogues that inhibit one-carbon transfer reactions required for de novo nucleotide synthesis.
“Aminopterin is the precursor of the currently used drugs methotrexate and pemetrexed, both of which are folate analogues that inhibit one-carbon transfer reactions required for de novo nucleotide synthesis (Figure 1, Figure 2a)(Walling, 2006).”
From Targeting Metabolism for Cancer Therapy (2017) · cites this paper as Walling, 2006

Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma
Vogelzang, N. J., Rusthoven, J. J., Symanowski, J., Denham, C., Kaukel, E., Ruffie, P., Gatzemeier, U., Boyer, M., Emri, S., Manegold, C., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.11.136 · Cited by 3,060 · see citing works
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy
Hanna, N., Shepherd, F. A., Fossella, F. V., Pereira, J. R., De Marinis, F., von Pawel, J., Gatzemeier, U., Tsao, T. C. Y., Pless, M., Muller, T., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.163 · Cited by 2,426 · see citing works
Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy
Early Breast Cancer Trialist's Collaborative Group (1992) · The Lancet · doi:10.1016/0140-6736(92)90997-h · Cited by 2,191 · see citing works
Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.
Focan, C., Steinberg, S. M., Blichert-Toft, M., Forbes, J., Collins, R. D., Anderson, S., Margreiter, R., Harwood, C. S., Andersen, K., Beighton, G., et al. (1998) · PubMed · Cited by 2,146 · see citing works
Polychemotherapy for early breast cancer: an overview of the randomised trials
(1998) · The Lancet · doi:10.1016/s0140-6736(98)03301-7 · Cited by 2,040 · see citing works
Temporary Remissions in Acute Leukemia in Children Produced by Folic Acid Antagonist, 4-Aminopteroyl-Glutamic Acid (Aminopterin)
Farber, S., Diamond, L. K., Mercer, R. D., Sylvester, R. F., & Wolff, J. A. (1948) · New England Journal of Medicine · doi:10.1056/nejm194806032382301 · Cited by 1,806 · see citing works
Combination Chemotherapy as an Adjuvant Treatment in Operable Breast Cancer
Bonadonna, G., Brusamolino, E., Valagussa, P., Rossi, A., Brugnatelli, L., Brambilla, C., Lena, M. D., Tancini, G., Bajetta, E., Musumeci, R., et al. (1976) · New England Journal of Medicine · doi:10.1056/nejm197602192940801 · Cited by 1,329 · see citing works
Adjuvant Cyclophosphamide, Methotrexate, and Fluorouracil in Node-Positive Breast Cancer — The Results of 20 Years of Follow-up
Bonadonna, G., Valagussa, P., Moliterni, A., Zambetti, M., & Brambilla, C. (1995) · New England Journal of Medicine · doi:10.1056/nejm199504063321401 · Cited by 1,048 · see citing works
A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study.
Loehrer, P. J., Einhorn, L. H., Elson, P. J., Crawford, E. D., Kuebler, P. J., Tannock, I. F., Raghavan, D., Stuart‐Harris, R., Sarosdy, M. F., & Lowe, B. A. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.7.1066 · Cited by 981 · see citing works
Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Physiologic and clinical implications
Ross, J. F., Chaudhuri, P. K., & Ratnam, M. (1994) · Cancer · doi:10.1002/1097-0142(19940501)73:9 · Cited by 886 · see citing works
A Southwest Oncology Group study
Jenkins, T. R., Tangen, C. M., Macdonald, J. S., Weiss, G. R., Chapman, R. M., & Hantel, A. (1993) · Cited by 773 · see citing works
A phase II study
Rougier, P. R., Adenis, A., Ducreux, M. P., Forni, M. D., Bonneterre, J. M., Dembak, M., Clouet, P., Lebecq, A., Baille, P., Lefresne-Soulas, F., et al. (2000) · European Journal of Cancer · doi:10.1016/s0959-8049(00)00072-1 · Cited by 751 · see citing works
Potocytosis: Sequestration and Transport of Small Molecules by Caveolae
Anderson, R. G. W., Kamen, B. A., Rothberg, K. G., & Lacey, S. W. (1992) · Science · doi:10.1126/science.1310359 · Cited by 734 · see citing works
Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors.
Johnston, P. G., Lenz, H.-J., Leichman, C. G., Danenberg, K. D., Allegra, C. J., Danenberg, P. V., & Leichman, L. (1995) · PubMed · Cited by 672 · see citing works
Randomized Phase III Study of Cisplatin With or Without Raltitrexed in Patients With Malignant Pleural Mesothelioma: An Intergroup Study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada
van Meerbeeck, J. P., Gaafar, R. M., Manegold, C., van Klaveren, R. J., Marck, E. A. V., Vincent, M. D., Legrand, C., Bottomley, A., Debruyne, C., & Giaccone, G. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.20005.14.589 · Cited by 617 · see citing works
Caveolae: where incoming and outgoing messengers meet.
Anderson, R. G. W. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.23.10909 · Cited by 613 · see citing works
A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors.
Logothetis, C. J., Dexeus, F. H., Finn, L., Sella, A., Amato, R. J., Ayala, A. G., & Kilbourn, R. G. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.6.1050 · Cited by 607 · see citing works
LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes.
Shih, C., Chen, V. J., Gossett, L. S., Gates, S. B., MacKellar, W. C., Habeck, L. L., Shackelford, K. A., Mendelsohn, L. G., Soose, D. J., Patel, V. F., et al. (1997) · PubMed · Cited by 560 · see citing works
Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women.
Fossati, R., Confalonieri, C., Torri, V., Ghislandi, E., Penna, A., Pistotti, V., Tinazzi, A., & Liberati, A. M. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.10.3439 · Cited by 543 · see citing works
Effect of Methotrexate Therapy upon Choriocarcinoma and Chorioadenoma
Li, M. C., Hertz, R., & Spencer, D. B. (1956) · Experimental Biology and Medicine · doi:10.3181/00379727-93-22757 · Cited by 514 · see citing works
Comparison of Gemcitabine Versus the Matrix Metalloproteinase Inhibitor BAY 12-9566 in Patients With Advanced or Metastatic Adenocarcinoma of the Pancreas: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group
Moore, M. J., Hamm, J. T., Dancey, J. E., Eisenberg, P. D., Dagenais, M., Fields, A. L. A., Hagan, K., Greenberg, B., Colwell, B., Zee, B. C.-Y., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.02.098 · Cited by 395 · see citing works
Childhood Leukemias
Pui, C.-H. (1995) · New England Journal of Medicine · doi:10.1056/nejm199506153322407 · Cited by 391 · see citing works
Clinical Pharmacodynamics of High-Dose Methotrexate in Acute Lymphocytic Leukemia
Evans, W. E., Crom, W. R., Abromowitch, M., Dodge, R., Look, A. T., Bowman, W. P., George, S. L., & Pui, C. (1986) · New England Journal of Medicine · doi:10.1056/nejm198602203140803 · Cited by 390 · see citing works
Sequential high-dose methotrexate and fluorouracil combined with doxorubicin--a step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group.
Wils, J., Klein, H. O., Wagener, D. J. T., Bleiberg, H., Reis, H. E., Korsten, F. W., Conroy, T., Fickers, M. M. F., Leyvraz, S., & Buyse, M. E. (1991) · Journal of Clinical Oncology · doi:10.1200/jco.1991.9.5.827 · Cited by 388 · see citing works
A randomized comparison of indwelling pleural catheter and doxycycline pleurodesis in the management of malignant pleural effusions
Putnam, J. B., Light, R. W., Rodriguez, R. M., Ponn, R. B., Olak, J., Pollak, J. S., Lee, R. B., Payne, D. K., Graeber, G., & Kovitz, K. L. (1999) · Cancer · doi:10.1002/(sici)1097-0142(19991115)86:10 · Cited by 385 · see citing works
Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale.
Colucci, G., Giuliani, F., Gebbia, V., Biglietto, M., Rabitti, P., Uomo, G., Cigolari, S., Testa, A., Maiello, E., & Lopez, M. (2002) · PubMed · Cited by 384 · see citing works
ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study.
Jackman, A. L., Taylor, G. A., Gibson, W., Kimbell, R., Brown, M., Calvert, H., Judson, I. R., & Lr, H. (1991) · PubMed · Cited by 357 · see citing works
Metabolic abnormalities in cobalamin (vitamin B 12 ) and folate deficiency
Allen, R. H., Stabler, S. P., Savage, D. G., & Lindenbaum, J. (1993) · The FASEB Journal · doi:10.1096/fasebj.7.14.7901104 · Cited by 352 · see citing works
Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival.
Lenz, H.-J., Leichman, C. G., Danenberg, K. D., Danenberg, P. V., Groshen, S. G., Cohen, H., Laine, L., Crookes, P. F., Silberman, H., Baranda, J. C., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.1.176 · Cited by 347 · see citing works
Determinants of caregiving experiences and mental health of partners of cancer patients
Nijboer, C., Triemstra, M., Tempelaar, R., Sanderman, R., & van den Bos, G. A. M. (1999) · Cancer · doi:10.1002/(sici)1097-0142(19990815)86:4 · Cited by 334 · see citing works
Digging into Caveolae
Parton, R. G., & Simons, K. (1995) · Science · doi:10.1126/science.7660120 · Cited by 316 · see citing works
Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma
Colucci, G., Giuliani, F., Gebbia, V., Biglietto, M., Rabitti, P., Uomo, G., Cigolari, S., Testa, A., Maiello, E., & Lopez, M. (2002) · Cancer · doi:10.1002/cncr.10323 · Cited by 307 · see citing works
A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer
Oettle, H., Richards, D., Ramanathan, R. K., Laethem, J. V., Peeters, M., Fuchs, M., Zimmermann, A. H., John, W. J., Hoff, D. V., Arning, M., et al. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi309 · Cited by 305 · see citing works
Pulmonary blastomas
Koss, M. N., Hochholzer, L., & O’Leary, T. J. (1991) · Cancer · doi:10.1002/1097-0142(19910501)67:9 · Cited by 272 · see citing works
A dideazatetrahydrofolate analog lacking a chiral center at C-6: N-[4-[2-(2-amino-3,4-dihydro-4-oxo-7H-pyrrolo[2,3-d]pyrimidin-5yl)ethyl[benzoyl]-L-glutamic acid is an inhibitor of thymidylate synthase
Taylor, E. C., Kuhnt, D., Shih, C., Rinzel, S. M., Grindey, G. B., Barredo, J. C., Jannatipour, M., & Moran, R. G. (1992) · Journal of Medicinal Chemistry · doi:10.1021/jm00101a023 · Cited by 254 · see citing works
The methotrexate story: A paradigm for development of cancer chemotherapeutic agents
Huennekens, F. M. (1994) · Advances in Enzyme Regulation · doi:10.1016/0065-2571(94)90025-6 · Cited by 251 · see citing works
Phase II Study of Pemetrexed With and Without Folic Acid and Vitamin B12 as Front-Line Therapy in Malignant Pleural Mesothelioma
Scagliotti, G. V., Shin, D.-M., Kindler, H. L., Vasconcelles, M. J., Keppler, U., Manegold, C., Burris, H. A., Gatzemeier, U., Blatter, J., Symanowski, J. T., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.06.122 · Cited by 251 · see citing works
Homocysteine and methylmalonic acid: Markers to predict and avoid toxicity from pemetrexed therapy
Niyikiza, C., Baker, S. D., Seitz, D. E., Walling, J. M., Nelson, K., Rusthoven, J. J., Stabler, S. P., Paoletti, P., Calvert, A. H., & Allen, R. H. (2002) · PubMed · doi:10.25405/ncl.34649535 · Cited by 248 · see citing works
Self-citation
Evaluation of cancer information on the Internet
Biermann, J. S., Golladay, G. J., Greenfield, M. L. V. H., & Baker, L. H. (1999) · Cancer · doi:10.1002/(sici)1097-0142(19990801)86:3 · Cited by 240 · see citing works
Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group.
(1992) · PubMed · Cited by 240 · see citing works
A potent antitumour quinazoline inhibitor of thymidylate synthetase: Synthesis, biological properties and therapeutic results in mice
Jones, T. R., Calvert, H., Jackman, A. L., Brown, S. J., Jones, M. A., & Harrap, K. R. (1981) · European Journal of Cancer (1965) · doi:10.1016/0014-2964(81)90206-1 · Cited by 239 · see citing works
Chemotherapy in malignant pleural mesothelioma. A review.
Ong, S. T., & Vogelzang, N. J. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.3.1007 · Cited by 225 · see citing works
Treatment of osteosarcoma of the extremities with the T-10 protocol, with emphasis on the effects of preoperative chemotherapy with single-agent high-dose methotrexate: a Scandinavian Sarcoma Group study.
Sæter, G., Alvegård, T. A., Elomaa, I., Stenwig, A. E., Holmström, T., & Solheim, Ø. P. (1991) · Journal of Clinical Oncology · doi:10.1200/jco.1991.9.10.1766 · Cited by 224 · see citing works
Response of brain metastases from breast cancer to systemic chemotherapy
Boogerd, W. J., Dalesio, O., Bais, E. M., & van der Sande, J. J. (1992) · Cancer · doi:10.1002/1097-0142(19920215)69:4 · Cited by 224 · see citing works
Multitargeted Antifolate LY231514 as First-Line Chemotherapy for Patients With Advanced Non–Small-Cell Lung Cancer: A Phase II Study
Rusthoven, J. J., Eisenhauer, E. A., Butts, C. A., Gregg, R. W., Dancey, J. E., Fisher, B., & Iglesias, J. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.4.1194 · Cited by 216 · see citing works
Patient characteristics associated with high-risk methotrexate concentrations and toxicity.
Relling, M. V., Fairclough, D. C., Ayers, D. M., Crom, W. R., Rodman, J. H., Pui, C., & Evans, W. E. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.8.1667 · Cited by 215 · see citing works
Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study Group.
Cocconi, G., Cunningham, D., Cutsem, E. V., François, É., Gustavsson, B., van Hazel, G., Kerr, D. J., Possinger, K., & Hietschold, S. M. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.9.2943 · Cited by 215 · see citing works
Enzymatic synthesis of folylpolyglutamates. Characterization of the reaction and its products.
McGuire, J. J., Hsieh, P., Coward, J. K., & Bertino, J. R. (1980) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)70697-8 · Cited by 213 · see citing works
Carrier- and receptor-mediated transport of folate antagonists targeting folate-dependent enzymes: correlates of molecular-structure and biological activity.
Westerhof, G. R., Schornagel, J. H., Kathmann, I., Jackman, A. L., Rosowsky, A., Forsch, R. A., Hynes, J. B., Boyle, F. T., Peters, G. J., & Pinedo, H. M. (1995) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)10494-x · Cited by 204 · see citing works
Final results of a randomised trial comparing ‘Tomudex’® (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer
Cunningham, D., Zalcberg, J. R., Räth, U., Oliver, I., Cutsem, E. V., Svensson, C., Seitz, J. F., Harper, P., Kerr, D. J., & Pérez-Manga, G. (1996) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a010800 · Cited by 203 · see citing works
Homologous membrane folate binding proteins in human placenta: cloning and sequence of a cDNA
Ratnam, M., Marquardt, H., Duhring, J. L., & Freisheim, J. H. (1989) · Biochemistry · doi:10.1021/bi00446a042 · Cited by 200 · see citing works
Isolation of a gene encoding a human reduced folate carrier (RFC1) and analysis of its expression in transport-deficient, methotrexate-resistant human breast cancer cells.
Moscow, J. A., Gong, M., He, R., Sgagias, M. K., Dixon, K. H., Anzick, S. L., Meltzer, P. S., & Cowan, K. H. (1995) · PubMed · Cited by 199 · see citing works
Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukemic effects in vivo. A rationale for high-dose methotrexate.
Masson, E., Relling, M. V., Synold, T. W., Liu, Q., Schuetz, J. D., Sandlund, J. T., Pui, C., & Evans, W. E. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118409 · Cited by 198 · see citing works
Blast cell methotrexate-polyglutamate accumulation in vivo differs by lineage, ploidy, and methotrexate dose in acute lymphoblastic leukemia.
Synold, T. W., Relling, M. V., Boyett, J. M., Rivera, G. K., Sandlund, J. T., Mahmoud, H. H., Crist, W., Pui, C., & We, E. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117552 · Cited by 194 · see citing works
Molecular cancer therapeutics
Press, H. (2001) · Cited by 190 · see citing works
Glutathione levels and variability in breast tumors and normal tissue
Perry, R. R., Mazetta, J., Levin, M., & BARRANCO, S. C. (1993) · Cancer · doi:10.1002/1097-0142(19930801)72:3 · Cited by 190 · see citing works
A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation
Rinaldi, D. A., Kuhn, J. G., Burris, H. A., Dorr, F. A., Rodriguez, G., Eckhardt, S. G., Jones, S. F., Woodworth, J. R., Baker, S. D., Langley, C., et al. (1999) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800050992 · Cited by 177 · see citing works
Methotrexate pharmacokinetics and prognosis in osteosarcoma.
Graf, N. M., Winkler, K., Betlemovic, M., Fuchs, N., & Bode, U. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.7.1443 · Cited by 174 · see citing works
Folate and antifolate pharmacology.
Kamen, B. A. (1997) · PubMed · Cited by 173 · see citing works
UPDATE ON CHEMOTHERAPY FOR ADVANCED BLADDER CANCER
ROSENBERG, J. E., Carroll, P. R., & Small, E. J. (2005) · The Journal of Urology · doi:10.1097/01.ju.0000162039.38023.5f · Cited by 167 · see citing works
Differential stereospecificities and affinities of folate receptor isoforms for folate compounds and antifolates
Xin, W., Feng, S., Freisheim, J. H., Gentry, L. E., & Ratnam, M. (1992) · Biochemical Pharmacology · doi:10.1016/0006-2952(92)90089-2 · Cited by 167 · see citing works
Design of thymidylate synthase inhibitors using protein crystal structures: the synthesis and biological evaluation of a novel class of 5-substituted quinazolinones
Webber, S. E., Bleckman, T. M., Attard, J. J., Deal, J. G., Kathardekar, V., Welsh, K. M., Webber, S., Janson, C. A., & Matthews, D. A. (1993) · Journal of Medicinal Chemistry · doi:10.1021/jm00058a010 · Cited by 162 · see citing works
Accumulation of high levels of methotrexate polyglutamates in lymphoblasts from children with hyperdiploid (greater than 50 chromosomes) B-lineage acute lymphoblastic leukemia: a Pediatric Oncology Group study
Whitehead, V. M., Vuchich, M.-J., Lauer, S. J., Mahoney, D. H., Carroll, A. J., Shuster, J. J., Esseltine, D. W., Payment, C., Look, A. T., & Akabutu, J. J. (1992) · Blood · doi:10.1182/blood.v80.5.1316.bloodjournal8051316 · Cited by 160 · see citing works
Ten years' experience with methotrexate and folinic acid as primary therapy for gestational trophoblastic disease
Berkowitz, R. S., GOLDSTEIN, D. P., & Bernstein, M. R. (1986) · Gynecologic Oncology · doi:10.1016/0090-8258(86)90123-x · Cited by 157 · see citing works
Mechanisms of methotrexate resistance in osteosarcoma.
Guo, W., Healey, J. H., Meyers, P. A., Ladanyi, M., Huvos, A. G., Bertino, J. R., & Gorlick, R. G. (1999) · PubMed · Cited by 152 · see citing works
Initial phase I evaluation of the novel thymidylate synthase inhibitor, LY231514, using the modified continual reassessment method for dose escalation.
Rinaldi, D. A., Burris, H. A., Dorr, F. A., Woodworth, J. R., Kuhn, J. G., Eckardt, J. R., Rodriguez, G., Corso, S. W., Jones, S. F., & Langley, C. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.11.2842 · Cited by 152 · see citing works
Clinical and Pharmacokinetic Phase I Study of Multitargeted Antifolate (LY231514) in Combination With Cisplatin
Thödtmann, R., Depenbrock, H., Dumez, H., Blatter, J., Johnson, R. D., van Oosterom, A., & Hanauske, A. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.10.3009 · Cited by 151 · see citing works
Phase I Clinical and Pharmacokinetic Study of Pemetrexed and Carboplatin in Patients With Malignant Pleural Mesothelioma
Hughes, A., Calvert, P. M., Azzabi, A., Plummer, R., Johnson, R., Rusthoven, J., Griffin, M., Fishwick, K., Boddy, A. V., Verrill, M. W., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.10.073 · Cited by 147 · see citing works
Amplification of the dihydrofolate reductase gene is a mechanism of acquired resistance to methotrexate in patients with acute lymphoblastic leukemia and is correlated with p53 gene mutations
Göker, E., Waltham, M. C., Kheradpour, A., Trippett, T. M., Mazumdar, M., Elisseyeff, Y., Schnieders, B., Steinherz, P. G., Tan, C. W., & Berman, E. (1995) · Blood · doi:10.1182/blood.v86.2.677.bloodjournal862677 · Cited by 143 · see citing works
Dihydrofolate reductase. The stereochemistry of inhibitor selectivity.
Matthews, D. A., Bolin, J. T., Burridge, J. M., Filman, D. J., Volz, K. W., & Kraut, J. (1985) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)89744-7 · Cited by 141 · see citing works
High-dose methotrexate in the treatment of malignant mesothelioma of the pleura. A phase II study
Solheim, Ø. P., Sæter, G., Finnanger, A., & Stenwig, A. (1992) · British Journal of Cancer · doi:10.1038/bjc.1992.200 · Cited by 139 · see citing works
Quality of life during chemotherapy in patients with symptomatic advanced colorectal cancer
Glimelius, B. L. G., Hoffman, K., Graf, W., Påhlman, L., Sjödén, P., & Nordic Gastrointestinal Tumor Adjuvant Therapy Group (1994) · Cancer · doi:10.1002/1097-0142(19940201)73:3 · Cited by 136 · see citing works
ZD1694: A novel thymidylate synthase inhibitor with substantial activity in the treatment of patients with advanced colorectal cancer. Tomudex Colorectal Study Group.
Zalcberg, J. R., Cunningham, D., Cutsem, E. V., François, É., Schornagel, J. H., Adenis, A., Green, M., Iveson, A., Azab, M., & Seymour, I. J. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.3.716 · Cited by 129 · see citing works
Combination of Raltitrexed and Oxaliplatin Is an Active Regimen in Malignant Mesothelioma: Results of a Phase II Study
Fizazi, K. S., Doubre, H., Chevalier, T. L., Riviere, A., Viala, J., Daniel, C., Robert, L., Barthélemy, P., Fandi, A., & Ruffiè, P. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.123 · Cited by 129 · see citing works
Characterization of a Mutation in the Reduced Folate Carrier in a Transport Defective L1210 Murine Leukemia Cell Line
Brigle, K. E., Spinella, M. J., Sierra, E. E., & Goldman, I. D. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.39.22974 · Cited by 125 · see citing works
Phase I clinical trials.
Sk, C., Selawry, O. S., & Slavík, M. (1977) · PubMed · Cited by 125 · see citing works
Distinguishing between Folate Receptor-α-mediated Transport and Reduced Folate Carrier-mediated Transport in L1210 Leukemia Cells
Spinella, M. J., Brigle, K. E., Sierra, E. E., & Goldman, I. D. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.14.7842 · Cited by 124 · see citing works
Prognostic importance of thymidylate synthase expression in early breast cancer.
Pestalozzi, B. C., Peterson, H. F., Gelber, R. D., Goldhirsch, A., Gusterson, B. A., Trihia, H., Lindtner, J., Cortés-Funes, H., Simmoncini, E., Byrne, M., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.5.1923 · Cited by 123 · see citing works
Phase II trial of pemetrexed disodium (ALIMTA®, LY231514) in chemotherapy-naïve patients with advanced non-small-cell lung cancer
Clarke, S. J., Abratt, R. P., Goedhals, L., Boyer, M. J., Millward, M. J., & Ackland, S. P. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf115 · Cited by 122 · see citing works
Effect of route of administration and effusions on methotrexate pharmacokinetics.
Wan, S. H., Huffman, D. H., Azarnoff, D. L., Stephens, R. J., & Hoogstraten, B. (1974) · PubMed · Cited by 120 · see citing works
LYME BORRELIOSIS IN BELGIUM
Bigaignon, G., Goubau, P., Desmyter, J., & Vandepitte, J. (1987) · The Lancet · doi:10.1016/s0140-6736(87)90191-7 · Cited by 120 · see citing works
Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma
Ulrich-Pur, H., Raderer, M., Kornek, G. V., Schüll, B., Schmid, K., Haider, K., Kwasny, W., Depisch, D., Schneeweiß, B., Lang, F., et al. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6600883 · Cited by 117 · see citing works
ALIMTA® (pemetrexed disodium) as second-line treatment ofnon-small-cell lung cancer: a phase II study
Smit, E. F., Mattson, K. V., von Pawel, J., Manegold, C., Clarke, S. J., & Postmus, P. E. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg099 · Cited by 117 · see citing works
Studies of the metabolism of methotrexate by intestinal flora—I
Valerino, D. M., Johns, D. G., Zaharko, D. S., & Oliverio, V. T. (1972) · Biochemical Pharmacology · doi:10.1016/0006-2952(72)90125-6 · Cited by 115 · see citing works
Human papillomavirus DNA in plasma of patients with cervical cancer
Pornthanakasem, W., Shotelersuk, K., Termrungruanglert, W., Voravud, N., Niruthisard, S., & Mutirangura, A. (2001) · BMC Cancer · doi:10.1186/1471-2407-1-2 · Cited by 112 · see citing works
Biochemical effects of a quinazoline inhibitor of thymidylate synthetase, N-(4-(N-((2-amino-4-hydroxy-6-quinazolinyl)methyl)prop-2-ynylamino)benzoyl)-l-glutamic acid (CB3717), on human lymphoblastoid cells
Jackson, R., Jackman, A. L., & Calvert, A. H. (1983) · Biochemical Pharmacology · doi:10.1016/0006-2952(83)90150-8 · Cited by 111 · see citing works
Role of thymidylate synthase in the antitumor activity of the multitargeted antifolate, LY231514.
Schultz, R. M., Patel, V. F., Worzalla, J. F., & Shih, C. (1999) · PubMed · Cited by 111 · see citing works
Increased frequency ofATM mutations in breast carcinoma patients with early onset disease and positive family history
Teraoka, S. N., Malone, K. E., Doody, D. R., Suter, N. M., Ostrander, E. A., Daling, J. R., & CONCANNON, P. J. (2001) · Cancer · doi:10.1002/1097-0142(20010801)92:3 · Cited by 111 · see citing works
Lack of functional retinoblastoma protein mediates increased resistance to antimetabolites in human sarcoma cell lines.
Li, W., Fan, J., Hochhauser, D., Banerjee, D., Zieliński, Z., Almasan, A., Yin, Y., Kelly, R., Wahl, G. M., & Bertino, J. R. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.22.10436 · Cited by 108 · see citing works
ZD1694 (Tomudex): A new thymidylate synthase inhibitor with activity in colorectal cancer
Jackman, A. L., Farrugia, D., Gibson, W. H., Kimbell, R., Harrap, K. R., Stephens, T. C., Azab, M., & Boyle, F. T. (1995) · European Journal of Cancer · doi:10.1016/0959-8049(95)00166-g · Cited by 105 · see citing works
Mechanisms of acquired resistance to the quinazoline thymidylate synthase inhibitor ZD1694 (Tomudex) in one mouse and three human cell lines
Jackman, A. L., Kèlland, L. R., Kimbell, R., Brown, M., Gibson, W. H., Aherne, G. W., Hardcastle, A., & Boyle, F. T. (1995) · British Journal of Cancer · doi:10.1038/bjc.1995.178 · Cited by 102 · see citing works
Phase II study of first-line LY231514 (multi-targeted antifolate) in patients with locally advanced or metastatic colorectal cancer: An NCIC Clinical Trials Group study
Cripps, C., Burnell, M. J., Jolivet, J., Batist, G., Lofters, W., Dancey, J. E., Iglesias, J., Fisher, B., & Eisenhauer, E. A. (1999) · Annals of Oncology · doi:10.1023/a:1008372529239 · Cited by 99 · see citing works
Modulation of anti-metabolite effects
Jackman, A. L., Taylor, G. A., Calvert, H., & Harrap, K. R. (1984) · Biochemical Pharmacology · doi:10.1016/0006-2952(84)90089-3 · Cited by 97 · see citing works
Presence of 2,4‐diamino‐N10‐methylpteroic acid after high‐dose methotrexate
Donehower, R. C., Hande, K. R., Drake, J. C., & Chabner, B. A. (1979) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt197926163 · Cited by 95 · see citing works
A randomized trial of cisplatin versus cisplatin plus methotrexate in advanced cancer of the urothelial tract.
Hillcoat, B. L., Raghavan, D., Matthews, J., Kefford, R. F., Yuen, K., Woods, R., Olver, I., Bishop, J. F., Pearson, B., & COOREY, G. J. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.6.706 · Cited by 95 · see citing works
Phase II study of the multitargeted antifolate LY231514 (ALIMTA™, MTA, pemetrexed disodium) in patients with advanced pancreatic cancer
Miller, K. D., Picus, J., Blanke, C. D., John, W. J., Clark, J. W., Shulman, L. N., Thornton, D., Rowinsky, E. K., & Loehrer, P. J. (2000) · Annals of Oncology · doi:10.1023/a:1008305205159 · Cited by 94 · see citing works
Resistance Mechanisms to Methotrexate in Tumors
Bertino, J. R., Göker, E., Gorlick, R. G., Li, W. W., & Banerjee, D. (1996) · Stem Cells · doi:10.1002/stem.140005 · Cited by 93 · see citing works
Molecular and cellular biology of the human reduced folate carrier
Matherly, L. H. (2001) · Progress in nucleic acid research and molecular biology · doi:10.1016/s0079-6603(01)67027-2 · Cited by 92 · see citing works
AG337, a novel lipophilic thymidylate synthase inhibitor: in vitro and in vivo preclinical studies
Webber, S. E., Bartlett, C. A., Boritzki, T. J., Hilliard, J. A., Howland, E. F., Johnston, A. L., Kosa, M. B., Margosiak, S. A., Morse, C. A., & Shetty, B. V. (1996) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800050422 · Cited by 91 · see citing works
A new analogue of 10-deazaaminopterin with markedly enhanced curative effects against human tumor xenografts in mice
Sirotnak, F. M., DeGraw, J. I., Colwell, W. T., & Piper, J. R. (1998) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800050823 · Cited by 91 · see citing works
Raltitrexed: current clinical status and future directions
Cutsem, E. V., Cunningham, D., Maroun, J. A., Cervantes, A. M. R., & Glimelius, B. L. G. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf054 · Cited by 89 · see citing works
THE “INDUCTION” OF DIHYDROFOLIC REDUCTASE ACTIVITY IN LEUKOCYTES AND ERYTHROCYTES OF PATIENTS TREATED WITH AMETHOPTERIN*
Bertino, J. R., Donohue, D. M., Simmons, B. S., Gabrio, B. W., Silber, R., & Huennekens, F. M. (1963) · Journal of Clinical Investigation · doi:10.1172/jci104735 · Cited by 89 · see citing works
Pemetrexed disodium in recurrent locally advanced or metastatic squamous cell carcinoma of the head and neck
Pivot, X. B., Raymond, É., Laguerre, B., Degardin, M., Cals, L., Armand, J., Lefebvre, J.-L., Gedouin, D., Ripoche, V., Kayitalire, L., et al. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.2010 · Cited by 88 · see citing works
Mechanism of inhibition of dihydrofolate reductases from bacterial and vertebrate sources by various classes of folate analogues
Stone, S. R., & Morrison, J. F. (1986) · Biochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology · doi:10.1016/0167-4838(86)90067-1 · Cited by 86 · see citing works
A Phase I and pharmacokinetic study of LY231514, the multitargeted antifolate
McDonald, A. C., Vasey, P. A., Adams, L., Walling, J. M., Woodworth, J. R., Abrahams, T., McCarthy, S. P., Bailey, N. P., Siddiqui, N. A., Lind, M., et al. (1998) · PubMed · doi:10.25405/ncl.34641321 · Cited by 83 · see citing works
Self-citation
Human gamma-glutamyl hydrolase: cloning and characterization of the enzyme expressed in vitro.
Yao, R., Schneider, E., Ryan, T. J., & Galivan, J. H. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.19.10134 · Cited by 83 · see citing works
Randomized Phase II Trial of Pemetrexed Combined With Either Cisplatin or Carboplatin in Untreated Extensive-Stage Small-Cell Lung Cancer
Socinski, M. A., Weissman, C., Hart, L. L., Beck, J. T., Choksi, J. K., Hanson, J. P., Prager, D., Monberg, M., Ye, Z., & Obasaju, C. K. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.7016 · Cited by 82 · see citing works
Clinically relevant drug–drug interactions in oncology
McLeod, H. L. (1998) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1998.00719.x · Cited by 80 · see citing works
Trimetrexate in malignant mesothelioma: A Cancer and Leukemia Group B Phase II study.
Vogelzang, N. J., Weissmann, L. B., Herndon, J. E., Antman, K. H., Cooper, M. R., Corson, J. M., & Green, M. R. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.7.1436 · Cited by 79 · see citing works
Randomized phase III trial of edatrexate versus methotrexate in patients with metastatic and/or recurrent squamous cell carcinoma of the head and neck: a European Organization for Research and Treatment of Cancer Head and Neck Cancer Cooperative Group study.
Schornagel, J. H., Verweij, J., de Mulder, P. H. M., Cognetti, F., Vermorken, J. B., Cappelaere, P., Armand, J., Wildiers, J., de Graeff, A., & Clavel, M. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.7.1649 · Cited by 78 · see citing works
Genomic organization of the human folate receptor genes on chromosome 11q13
Ragoussis, J., Senger, G., Trowsdale, J., & Campbell, I. (1992) · Genomics · doi:10.1016/s0888-7543(05)80236-8 · Cited by 78 · see citing works
A phase III comparison trial of streptozotocin, mitomycin, and 5-fluorouracil with cisplatin, cytosine arabinoside, and caffeine in patients with advanced pancreatic carcinoma
Kelsen, D. P., Hudis, C. A., Niedzwiecki, D., Dougherty, J., Casper, E. S., Botet, J. F., Vinciguerra, V. P., & Rosenbluth, R. J. (1991) · Cancer · doi:10.1002/1097-0142(19910901)68:5 · Cited by 77 · see citing works
Phase II study of 10-ethyl-10-deaza-aminopterin in patients with stage III and IV non-small-cell lung cancer.
Shum, K. Y., Kris, M. G., Gralla, R. J., Burke, M. T., Marks, L. D., & Heelan, R. T. (1988) · Journal of Clinical Oncology · doi:10.1200/jco.1988.6.3.446 · Cited by 77 · see citing works
Pharmacokinetic Optimisation of Cancer Chemotherapy
Masson, E., & Zamboni, W. C. (1997) · Clinical Pharmacokinetics · doi:10.2165/00003088-199732040-00005 · Cited by 76 · see citing works
Increase of dihydrofolate reductase activity in cultured mammalian cells after exposure to methotrexate.
Hillcoat, B. L., Swett, V., & Bertino, J. R. (1967) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.58.4.1632 · Cited by 75 · see citing works
A randomized phase III study comparing gemcitabine + pemetrexed versus gemcitabine in patients with locally advanced and metastatic pancreas cancer
Richards, D., Kindler, H. L., Oettle, H., Ramanathan, R. K., Laethem, J. V., Peeters, M., Fuchs, M., John, W. J., Arning, M., & Hoff, D. D. V. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.14_suppl.4007 · Cited by 74 · see citing works
Phase I trial of ZD1694, a new folate-based thymidylate synthase inhibitor, in patients with solid tumors.
Clarke, S. J., Hanwell, J., de Boer, M., Planting, A., Verweij, J., Walker, M., Smith, R. P., Jackman, A. L., Hughes, L. R., Harrap, K. R., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.5.1495 · Cited by 73 · see citing works
Incremental angiogenesis assessed by color doppler ultrasound in the tumorigenesis of ovarian neoplasms
Wu, C., Lee, C., Chen, T.-M., Shyu, M., Hsieh, C., Chen, H.-Y., & Hsieh, F. (1994) · Cancer · doi:10.1002/1097-0142(19940215)73:4 · Cited by 70 · see citing works
Implication of vascular endothelial growth factor and p53 status for angiogenesis in noninvasive colorectal carcinoma
Kondo, Y., Arii, S., Furutani, M., Isigami, S., Mori, A., Onodera, H., Chiba, T., & Imamura, M. (2000) · Cancer · doi:10.1002/(sici)1097-0142(20000415)88:8 · Cited by 69 · see citing works
New folate analogs of the 10-deaza-aminopterin series: markedly increased antitumor activity of the 10-ethyl analog compared to the parent compound and methotrexate against some human tumor xenografts in nude mice.
Schmid, F. A., Sirotnak, F. M., Otter, G. M., & DeGraw, J. I. (1985) · PubMed · Cited by 69 · see citing works
Synthesis and antitumor activity of 10-propargyl-10-deazaaminopterin
DeGraw, J. I., Colwell, W. T., Piper, J. R., & Sirotnak, F. M. (1993) · Journal of Medicinal Chemistry · doi:10.1021/jm00067a020 · Cited by 69 · see citing works
Defective transport as a mechanism of acquired resistance to methotrexate in patients with acute lymphocytic leukemia
Trippett, T. M., Śchlemmer, S., Elisseyeff, Y., Göker, E., Wächter, M., Steinherz, P. G., Tan, C. R. C., Berman, E., Wright, J., & Rosowsky, A. (1992) · Blood · doi:10.1182/blood.v80.5.1158.1158 · Cited by 67 · see citing works
Increased expression and characterization of two distinct folate binding proteins in murine erythroleukemia cells
Brigle, K. E., Spinella, M. J., Westin, E. H., & Goldman, I. D. (1994) · Biochemical Pharmacology · doi:10.1016/0006-2952(94)90025-6 · Cited by 67 · see citing works
A phase II study of pemetrexed disodium (LY231514) in patients with locally recurrent or metastatic breast cancer
Miles, D. W., Smith, I. E., Coleman, R. E., Calvert, H., & Lind, M. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00117-4 · Cited by 66 · see citing works
Receptor- and Carrier-Mediated Transport Systems for Folates and Antifolates
Jansen, G. (1999) · Humana Press eBooks · doi:10.1007/978-1-59259-725-3_14 · Cited by 65 · see citing works
Increased Frequency of Expression of Elevated Dihydrofolate Reductase in T-Cell Versus B-Precursor Acute Lymphoblastic Leukemia in Children
Matherly, L. H., Taub, J. W., Wong, S. C., Simpson, P. M., Ekizian, R., Buck, S., Williamson, M. P., Amylon, M. D., Pullen, J., Camitta, B. M., et al. (1997) · Blood · doi:10.1182/blood.v90.2.578 · Cited by 64 · see citing works
Mechanisms of natural resistance to antifolates in human soft tissue sarcomas.
Li, W., Lin, J. T., Tong, W. P., Trippett, T. M., Brennan, M. F., & Bertino, J. R. (1992) · PubMed · Cited by 64 · see citing works
Thymidylate synthase expression in advanced colorectal cancer predicts for response to raltitrexed.
Farrugia, D., Ford, H. E. R., Cunningham, D., Danenberg, K. D., Danenberg, P. V., Brabender, J., McVicar, A. D., Aherne, G. W., Hardcastle, A., McCarthy, K., et al. (2003) · PubMed · Cited by 63 · see citing works
Edatrexate (10-ethyl-deaza-aminopterin) (NSC #626715) with or without leucovorin rescue for malignant mesothelioma. Sequential phase II trials by the cancer and leukemia group B.
Kindler, H. L., Belani, C. P., Herndon, J. E., Vogelzang, N. J., Suzuki, Y., & Green, M. R. (1999) · PubMed · Cited by 63 · see citing works
Renal function and the rate of disappearance of methotrexate from serum
Kristensen, L. �., Weismann, K., & Hutters, L. (1975) · European Journal of Clinical Pharmacology · doi:10.1007/bf00562319 · Cited by 63 · see citing works
Phase I and pharmacokinetic study of 10-propargyl-10-deazaaminopterin, a new antifolate.
Krug, L. M., Ng, K., Kris, M. G., Miller, V. A., Tong, W. P., Heelan, R. T., León, L. F., Leung, D. H. Y., Kelly, J., Grant, S. C., et al. (2000) · PubMed · Cited by 60 · see citing works
The biochemical pharmacology of the thymidylate synthase inhibitor, 2-desamino-2-methyl-N10-propargyl-5,8-dideazafolic acid (ICI 198583)
Jackman, A. L., Newell, D. R., Gibson, W. H., Jodrell, D. I., Taylor, G. A., Bishop, J. A. M., Hughes, L. R., & Calvert, H. (1991) · Biochemical Pharmacology · doi:10.1016/0006-2952(91)90586-t · Cited by 59 · see citing works
A novel class of monoglutamated antifolates exhibits tight-binding inhibition of human glycinamide ribonucleotide formyltransferase and potent activity against solid tumors.
Habeck, L. L., Leitner, T. A., Shackelford, K. A., Gossett, L. S., Schultz, R. M., Andis, S. L., Shih, C., Grindey, G. B., & Mendelsohn, L. G. (1994) · PubMed · Cited by 58 · see citing works
The activity of raltitrexed (Tomudex®) in malignant pleural mesothelioma
Baas, P., Ardizzoni, A., Grossi, F., Nackaerts, K. L., Numico, G., Marck, E. V., van de Vijver, M. J., Monetti, F., Smid-Geirnaerdt, M. J. A., van Zandwijk, N., et al. (2003) · European Journal of Cancer · doi:10.1016/s0959-8049(02)00668-8 · Cited by 58 · see citing works
Commentary on and reprint of Farber S, Diamond LK, Mercer RD, Sylvester RF, Wolff JA, Temporary remissions in acute leukemia in children produced by folic acid antagonist 4-aminopteroyl-glutamic acid (aminopterin), in New England Journal of Medicine (1948) 238:787–793
Lichtman, M. A., SPIVAK, J., Boxer, L. A., Shattil, S. J., & Henderson, E. S. (2000) · Elsevier eBooks · doi:10.1016/b978-012448510-5/50147-3 · Cited by 58 · see citing works
TomudexTM (ZD1694): from concept to care, a programme in rational drug discovery
Jackman, A. L., Harrap, K. R., & Boyle, F. T. (1996) · Investigational New Drugs · doi:10.1007/bf00194534 · Cited by 57 · see citing works
Phase II study of trimetrexate, fluorouracil, and leucovorin for advanced colorectal cancer.
Blanke, C. D., Kasimis, B. S., Schein, P. S., Capizzi, R. L., & Kurman, M. R. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.3.915 · Cited by 55 · see citing works
Preclinical cellular pharmacology of LY231514 (MTA): a comparison with methotrexate, LY309887 and raltitrexed for their effects on intracellular folate and nucleoside triphosphate pools in CCRF-CEM cells
Chen, V. J., Bewley, J. R., Andis, S. L., Schultz, R. M., Iversen, P., Shih, C., Mendelsohn, L. G., Seitz, D. E., & Tonkinson, J. L. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.751 · Cited by 55 · see citing works
Loss of Folic Acid Exporter Function with Markedly Augmented Folate Accumulation in Lipophilic Antifolate-resistant Mammalian Cells
Assaraf, Y. G., & Goldman, I. D. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.28.17460 · Cited by 55 · see citing works
The Mechanism of Action of Methotrexate III. Requirement of Free Intracellular Methotrexate for Maximal Suppression of [14C]Formate Incorporation into Nucleic Acids and Protein
White, J. C., Loftfield, S., & Goldman, I. D. (1975) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)10637-8 · Cited by 55 · see citing works
Phase II study of pemetrexed disodium (Alimta®) administered with oral folic acid in patients with advanced gastric cancer
Bajetta, E., Celio, L., Buzzoni, R., Ferrari, L., Marchianò, A. V., Martinetti, A., Longarini, R., Becerra, C. R., Ilardi, C. F., & John, W. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg406 · Cited by 54 · see citing works
Oral piritrexim, an effective treatment for metastatic urothelial cancer
de Wit, R., Kaye, S. B., Roberts, J., Stoter, G., Scott, J. E., & Verweij, J. (1993) · British Journal of Cancer · doi:10.1038/bjc.1993.71 · Cited by 53 · see citing works
Edatrexate, an Antifolate with Antitumor Activity: A Review
Grant, S. C., Kris, M. G., Young, C. W., & Sirotnak, F. M. (1993) · Cancer Investigation · doi:10.3109/07357909309020259 · Cited by 52 · see citing works
Resistance to antimetabolites
Peters, G., & Jansen, G. (1996) · Pure Amsterdam UMC · Cited by 52 · see citing works
Raltitrexed plus oxaliplatin (TOMOX) as first-line chemotherapy for metastatic colorectal cancer. A phase II study of the Italian Group for the Study of Gastrointestinal Tract Carcinomas (GISCAD)
Cascinu, S., Graziano, F., Ferraù, F., Catalano, V., Massacesi, C., Santini, D., Silva, R. R., Barni, S., Zaniboni, A., Battelli, N., et al. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf091 · Cited by 52 · see citing works
A Phase I clinical study of the antipurine antifolate lometrexol (DDATHF) given with oral folic acid
Laohavinij, S., Wedge, S. R., Lind, M., Bailey, N. P., Humphreys, A. C., Proctor, M., Chapman, F., Simmons, D., Oakley, A., Robson, L., et al. (1996) · Investigational New Drugs · doi:10.1007/bf00194536 · Cited by 49 · see citing works
10-propargyl-10-deazaaminopterin: an antifolate with activity in patients with previously treated non-small cell lung cancer.
Krug, L. M., Azzoli, C. G., Kris, M. G., Miller, V. A., Khokhar, N. Z., Tong, W. P., Ginsberg, M. S., Venkatraman, E. S., Tyson, L. B., Pizzo, B., et al. (2003) · PubMed · Cited by 49 · see citing works
Phase II trial of ZD1694 (TomudexTM) in patients with advanced pancreatic cancer
Pazdur, R., Meropol, N. J., Casper, E. S., Fuchs, C. S., Douglass, H. O., Vincent, M. D., & Abbruzzese, J. L. (1995) · Investigational New Drugs · doi:10.1007/bf00873144 · Cited by 48 · see citing works
Phase II trial of oral piritrexim in advanced, previously treated transitional cell cancer of bladder
Khorsand, M., Lange, J., Feun, L. G., Clendeninn, N. J., Collier, M. A., & Wilding, G. (1997) · Investigational New Drugs · doi:10.1023/a:1005860806635 · Cited by 47 · see citing works
Phase II study of the antifolate N10-propargyl-5,8-dideazafolic acid (CB 3717) in advanced breast cancer
Cantwell, B. M. J., Macaulay, V. M., Harris, A. L., Kaye, S. B., Smith, I. E., Milsted, R., & Calvert, H. (1988) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(88)90307-0 · Cited by 47 · see citing works
A multi-centre randomized phase II study of nolatrexed versus doxorubicin in treatment of Chinese patients with advanced hepatocellular carcinoma
Mok, T. S. K., Leung, T. W. T., Lee, S., Chao, Y., Chan, A. T. �., Huang, A. T., Lui, M.-C., Yeo, W., Chak, K., Johnston, A. L., et al. (1999) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800050982 · Cited by 47 · see citing works
Phase II study of pemetrexed in breast cancer patients pretreated with anthracyclines
Martín, M., Spielmann, M., Namer, M., duBois, A., Unger, C., Dodwell, D. J., Vodvarka, P., Lind, M., Calvert, H., Casado, A., et al. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg339 · Cited by 47 · see citing works
Chemotherapy for advanced bladder cancer.
Roth, B. J. (1996) · PubMed · Cited by 46 · see citing works
Phase II Study of Pemetrexed-Gemcitabine Combination in Patients with Advanced-Stage Non-Small Cell Lung Cancer
Monnerat, C., Chevalier, T. L., Kelly, K. L., Obasaju, C. K., Brahmer, J. R., Novello, S., Nakamura, T., Liepa, A. M., Bozec, L., Bunn, P. A., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0218 · Cited by 46 · see citing works
Phase I studies with trimetrexate: clinical pharmacology, analytical methodology, and pharmacokinetics.
Lin, J. T., Cashmore, A. R., Baker, M., Dreyer, R. N., Ernstoff, M. S., Marsh, J. C., Bertino, J. R., Whitfield, L. R., Delap, R., & Grillo-López, A. J. (1987) · PubMed · Cited by 45 · see citing works
Effects of impaired renal function on the pharmacokinetics of raltitrexed (Tomudex ZD1694)
Judson, I. R., Maughan, T., Beale, P. J., Primrose, J. M., Hoskin, P., Hanwell, J., Berry, C., Walker, M., & Sutcliffe, F. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.652 · Cited by 44 · see citing works
Cross-Resistance to the Lipid-Soluble Antifolate Trimetrexate in Human Carcinoma Cells With the Multidrug-Resistant Phenotype
Assaraf, Y. G., Molina, A., & SCHIMKE, R. T. (1989) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/81.4.290 · Cited by 44 · see citing works
Trial of sequential trimetrexate, fluorouracil, and high-dose leucovorin in previously treated patients with gastrointestinal carcinoma.
Conti, J. A., Kemeny, N. E., Seiter, K. P., Göker, E., Tong, W., André, M. P. E., Ragusa, K., & Bertino, J. R. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.4.695 · Cited by 43 · see citing works
Leucovorin Enhances Chtotoxicity of Trimetrexate/Fluorouracil, But Not Methotrexate/Fluorouracil, in CCRF-CEM Cells
Romanini, A., Li, W. W., Colofiore, J. R., & Bertino, J. R. (1992) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/84.13.1033 · Cited by 43 · see citing works
Preclinical Pharmacology Studies and the Clinical Development of a Novel Multitargeted Antifolate, MTA (LY231514)
Shih, C., & Thornton, D. (1999) · Humana Press eBooks · doi:10.1007/978-1-59259-725-3_8 · Cited by 43 · see citing works
Trimetrexate in the Treatment of Recurrent or Advanced Leiomyosarcoma of the Uterus: A Phase II Study of the Gynecologic Oncology Group
Smith, H. O., Blessing, J. A., & Vaccarello, L. (2002) · Gynecologic Oncology · doi:10.1006/gyno.2001.6482 · Cited by 43 · see citing works
Medical management of advanced gastric cancer
Hill, M. E., & Cunningham, D. (1998) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(98)90077-9 · Cited by 43 · see citing works
Phase I Clinical and Pharmacogenetic Trial of Irinotecan and Raltitrexed Administered Every 21 Days to Patients With Cancer
Stevenson, J. P., Redlinger, M., Kluijtmans, L. A. J., Sun, W., Algazy, K., Giantonio, B. J., Haller, D. G., Hardy, C. L., Whitehead, A. S., & O'Dwyer, P. J. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.20.4081 · Cited by 43 · see citing works
Enzymatic synthesis of folylpolyglutamates
McGuire, J. J. (1980) · Medical Entomology and Zoology · Cited by 41 · see citing works
Clinical pharmacokinetic and pharmacodynamic studies with the nonclassical antifolate thymidylate synthase inhibitor 3, 4-dihydro-2-amino-6-methyl-4-oxo-5-(4-pyridylthio)-quinazolone dihydrochloride (AG337) given by 24-hour continuous intravenous infusion.
Rafi, I., Taylor, G. A., Calvete, J. A., Boddy, A. V., Balmanno, K., Bailey, N. P., Lind, M., Calvert, H., Webber, S., & Jackson, R. (1995) · PubMed · Cited by 39 · see citing works
Phase I and clinical pharmacology study of trimetrexate administered weekly for three weeks.
Fanucchi, M. P., Walsh, D., Fleisher, M., Lokos, G., Williams, L., Cassidy, C., Vidal, P., Chou, T., Niedzwiecki, D., & Young, C. W. (1987) · PubMed · Cited by 39 · see citing works
Phase II study of a novel antifolate, N10-propargyl-5,8 dideazafolic acid (CB3717), in malignant mesothelioma.
Cantwell, B. M. J., Earnshaw, M., & Harris, A. L. (1986) · PubMed · Cited by 39 · see citing works
Antineoplastic Agents Drug Interactions of Clinical Significance
van Meerten, E., Verweij, J., & Schellens, J. H. M. (1995) · Drug Safety · doi:10.2165/00002018-199512030-00003 · Cited by 38 · see citing works
Multicenter non-randomized phase II study of raltitrexed (Tomudex) and oxaliplatin in non-pretreated metastatic colorectal cancer patients
Seitz, J. F., Bennouna, J., Paillot, B., Gamelin, E., François, É., Conroy, T., Raoul, J., Bécouarn, Y., Bertheault-Cvitkovic, F., Ychou, M., et al. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf183 · Cited by 38 · see citing works
Phase II trial of piritrexim in metastatic melanoma using intermittent, low-dose administration.
Feun, L. G., Gonzalez, R. C., Savaraj, N., Hanlon, J. T., Collier, M. A., Robinson, W. A., & Clendeninn, N. J. (1991) · Journal of Clinical Oncology · doi:10.1200/jco.1991.9.3.464 · Cited by 38 · see citing works
Pharmacokinetic and pharmacodynamic evaluation of the glycinamide ribonucleotide formyltransferase inhibitor AG2034.
McLeod, H. L., Cassidy, J., Powrie, R. H., Priest, D. G., Zorbas, M. A., Synold, T. W., Shibata, S., SPICER, D. V., Bissett, D., Pithavala, Y. K., et al. (2000) · PubMed · Cited by 37 · see citing works
Overview of the tolerability of ??Tomudex?? (raltitrexed): collective clinical experience in advanced colorectal cancer
Zalcberg, J. R. (1997) · Anti-Cancer Drugs · doi:10.1097/00001813-199708002-00004 · Cited by 37 · see citing works
INTERACTION BETWEEN METHOTREXATE AND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS
Daly, H. M., Boyle, J. J., Roberts, C. J., & Scott, G. L. (1986) · The Lancet · doi:10.1016/s0140-6736(86)90910-4 · Cited by 37 · see citing works
Second-line treatment with oxaliplatin + raltitrexed in patients with advanced colorectal cancer failing fluoropyrimidine/leucovorin-based chemotherapy
Scheithauer, W., Kornek, G. V., Schuell, B., Ulrich-Pur, H., Penz, M., Raderer, M., Lang, F., Schneeweiß, B., Lenauer, A., & Depisch, D. (2001) · Annals of Oncology · doi:10.1023/a:1011194712661 · Cited by 37 · see citing works
Preclinical and phase I clinical studies with the nonclassical antifolate thymidylate synthase inhibitor nolatrexed dihydrochloride given by prolonged administration in patients with solid tumors.
Rafi, I., Boddy, A. V., Calvete, J. A., Taylor, G. A., Newell, D. R., Bailey, N. P., Lind, M., Green, M., Hines, J., Johnstone, A., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.3.1131 · Cited by 37 · see citing works
Clinical studies with MTA
Calvert, A. H., & Walling, J. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.752 · Cited by 36 · see citing works
Self-citation
Result of two randomized trials comparing nolatrexed (Thymitaq™) versus methotrexate in patients with recurrent head and neck cancer
Pivot, X. B., Wadler, S., Kelly, C., Ruxer, R. L., Tortochaux, J., Stern, J. C., Belpomme, D., Humblet, Y., Domenge, C., Clendeninn, N. J., et al. (2001) · Annals of Oncology · doi:10.1023/a:1013185402896 · Cited by 36 · see citing works
A phase II study in advanced breast cancer: ZD1694 ('Tomudex') a novel direct and specific thymidylate synthase inhibitor
Smith, I., Jones, A. L., Spielmann, M., Namer, M., Green, M., Bonneterre, J. M., Wander, H. E., Hatschek, T., Wilking, N., Zalcberg, J. R., et al. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.386 · Cited by 35 · see citing works
Quinazoline antifolates inhibiting thymidylate synthase: variation of the N10 substituent
Jones, T. R., Calvert, H., Jackman, A. L., Eakin, M. A., Smithers, M. J., Betteridge, R. F., Newell, D. R., Hayter, A. J., & Stocker, A. (1985) · Journal of Medicinal Chemistry · doi:10.1021/jm00148a016 · Cited by 35 · see citing works
Posttranscriptionally Mediated Decreases in Folylpolyglutamate Synthetase Gene Expression in Some Folate Analogue-resistant Variants of the L1210 Cell
Roy, K. K., Egan, M. G., Sirlin, S., & Sirotnak, F. M. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.11.6903 · Cited by 35 · see citing works
A randomized phase III study of cisplatin with or without raltitrexed in patients (pts) with malignant pleural mesothelioma (MPM): an intergroup study of the EORTC Lung Cancer Group and NCIC
van Meerbeeck, J. P., Manegold, C., Gaafar, R. M., van Klaveren, R. J., Marck, E. A. V., Vincent, M., Legrand, C., Debruyne, C., & Giaccone, G. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.90140.7021 · Cited by 35 · see citing works
Phase I studies with the nonclassical antifolate nolatrexed dihydrochloride (AG337, THYMITAQ) administered orally for 5 days
Hughes, A. N., Rafi, I., Griffin, M., Calvert, A. H., Newell, D. R., Calvete, J. A., Johnston, A., Clendeninn, N. J., & Boddy, A. V. (1999) · PubMed · doi:10.25405/ncl.34593561 · Cited by 34 · see citing works
Metabolism, excretion and pharmacokinetics of a single dose of [ 14 C]-raltitrexed in cancer patients
Beale, P. J., Judson, I. R., Hanwell, J., Berry, C., Aherne, W., Hickish, T., Martin, P. D., & Walker, M. (1998) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800050787 · Cited by 34 · see citing works
Receptor- and carrier-mediated transport systems for folates and antifolates: exploitation for folate-based chemotherapy and immunotherapy
Jansen, G. (1999) · Pure Amsterdam UMC · Cited by 34 · see citing works
Piritrexim in Advanced, Refractory Carcinoma of the Urothelium (E3896): A Phase II Trial of the Eastern Cooperative Oncology Group
Roth, B. J., Manola, J. B., Dreicer, R., Graham, D. L., & Wilding, G. (2002) · Investigational New Drugs · doi:10.1023/a:1020675017737 · Cited by 33 · see citing works
Phase II study of 10-ethyl-10-deaza-aminopterin (10-EdAM; CGP 30 694) for stage IIIB or IV non-small cell lung cancer
Lee, J. S., Libshitz, H. I., Murphy, W. K., Jeffries, D. G., & Hong, W. K. (1990) · Investigational New Drugs · doi:10.1007/bf00171841 · Cited by 33 · see citing works
Probing the Folate-binding Site of Human Thymidylate Synthase by Site-directed Mutagenesis
Tong, Y., Liu-Chen, X., Ercikan-Abali, E. A., Zhao, S., Banerjee, D., Maley, F., & Bertino, J. R. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.47.31209 · Cited by 33 · see citing works
Cross-resistance to antifolates in multidrug resistant cell lines with P-glycoprotein or multidrug resistance protein expression
van Triest, B., Pinedo, H. M., Telleman, F., van der Wilt, C. L., Jansen, G., & Peters, G. J. (1997) · Biochemical Pharmacology · doi:10.1016/s0006-2952(97)82448-3 · Cited by 32 · see citing works
Tumor Resistance To Antimetabolites
Kinsella, A. R., & Smith, D. B. (1998) · General Pharmacology The Vascular System · doi:10.1016/s0306-3623(97)00383-2 · Cited by 32 · see citing works
Phase I Trial of Trimetrexate Glucuronate on a Five-Day Bolus Schedule: Clinical Pharmacology and Pharmacodynamics
Grochow, L. B., Noe, D. A., Dole, G., Rowinsky, E. K., Ettinger, D. S., Graham, M. L., McGuire, W. P., & Donehower, R. C. (1989) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/81.2.124 · Cited by 32 · see citing works
Understanding the Cancer Biology Universe: Enigmas, Context and Future Prospects
Coffey, D. S. (2002) · Cancer Biology & Therapy · doi:10.4161/cbt.1.5.223 · Cited by 32 · see citing works
Heparin: does it act as an antioxidant in vivo?
Lapenna, D., Mezzetti, A., de Gioia, S., Ciofani, G., Marzio, L., Ilio, C. D., & Cuccurullo, F. (1992) · Biochemical Pharmacology · doi:10.1016/0006-2952(92)90057-p · Cited by 31 · see citing works
Phase II study of Edatrexate in stage III and IV non-small-cell lung cancer
Souhami, R. L., Rudd, R., Spiro, S. G., Allen, R., Lamond, P., & Harper, P. (1992) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00685598 · Cited by 31 · see citing works
Trimetrexate in Relapsed T-Cell Lymphoma With Skin Involvement
Sarris, A. H., Phan, A. T., Duvic, M. A., Romaguera, J. E., McLaughlin, P. J., Mesina, O. M., King, K. M., Medeiros, L. J., Rassidakis, G. Z., Samuels, B. I., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.08.006 · Cited by 31 · see citing works
Protein kinase C activity and multidrug resistance in MOLT-3 human lymphoblastic leukemia cells resistant to trimetrexate.
Schwartz, G. K., Arkin, H., Holland, J. F., & Ohnuma, T. (1991) · PubMed · Cited by 31 · see citing works
Mutations in the gene for human dihydrofolate reductase: an unlikely cause of clinical relapse in pediatric leukemia after therapy with methotrexate.
Spencer, H. T., Sorrentino, B. P., Pui, C., Chunduru, S., Sleep, S. E. H., & Blakley, R. L. (1996) · PubMed · Cited by 31 · see citing works
Oxaliplatin plus raltitrexed and leucovorin-modulated 5-fluorouracil i.v. bolus: a salvage regimen for colorectal cancer patients
Comella, P., Casaretti, R., Crucitta, E., Vita, F. D., Palmeri, S., Avallone, A., Orditura, M., Lucia, L. D., Prete, S. D., Catalano, G., et al. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600414 · Cited by 30 · see citing works
Phase II study of edatrexate in chemotherapy-naive patients with metastatic breast cancer
Schornagel, J. H., van der Vegt, S., Verweij, J., de Graeff, A., Dullemond‐Westland, A. C., van Deijk, W. A., & Huinink, W. W. T. B. (1992) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a058258 · Cited by 30 · see citing works
A novel folate transport activity in human mesothelioma cell lines with high affinity and specificity for the new-generation antifolate, pemetrexed.
Wang, Y., Zhao, R., Chattopadhyay, S., & Goldman, I. D. (2002) · PubMed · Cited by 29 · see citing works
Inhibition of folate-dependent enzymes by 7-OH-methotrexate
Sholar, P. W., Baram, J., Seither, R. L., & Allegra, C. J. (1988) · Biochemical Pharmacology · doi:10.1016/0006-2952(88)90709-5 · Cited by 29 · see citing works

Flagged first, then by citations

1 of the 353 references couldn’t be matched to a known paper.

Sorted by citations

Targeting Metabolism for Cancer Therapy
Luengo, A., Gui, D. Y., & Vander Heiden, M. G. (2017) · Cell Chemical Biology · doi:10.1016/j.chembiol.2017.08.028 · Cited by 971 · see citing works
ABC Transporters in Multidrug Resistance and Pharmacokinetics, and Strategies for Drug Development
Choi, Y. H., & Yu, A. (2014) · Current Pharmaceutical Design · doi:10.2174/138161282005140214165212 · Cited by 633 · see citing works
Antifolates in cancer therapy: Structure, activity and mechanisms of drug resistance
Gonen, N., & Assaraf, Y. G. (2012) · Drug Resistance Updates · doi:10.1016/j.drup.2012.07.002 · Cited by 435 · see citing works
Molecular basis of antifolate resistance
Assaraf, Y. G. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9049-z · Cited by 338 · see citing works
Metabolic Codependencies in the Tumor Microenvironment
Dey, P., Kimmelman, A. C., & DePinho, R. A. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1211 · Cited by 342 · see citing works
Photocontrol of Antibacterial Activity: Shifting from UV to Red Light Activation
Wegener, M., Hansen, M. J., Driessen, A. J. M., Szymański, W., & Feringa, B. L. (2017) · Journal of the American Chemical Society · doi:10.1021/jacs.7b09281 · Cited by 325 · see citing works
Cancer Cells Tune the Signaling Pathways to Empower de Novo Synthesis of Nucleotides
Villa, E., Ali, E. S., Sahu, U., & Ben‐Sahra, I. (2019) · Cancers · doi:10.3390/cancers11050688 · Cited by 276 · see citing works
Therapy for Osteosarcoma
Chou, A. J., Geller, D. S., & Gorlick, R. G. (2008) · Pediatric Drugs · doi:10.2165/00148581-200810050-00005 · Cited by 275 · see citing works
Zinc coordination complexes as anticancer agents
Pellei, M., Bello, F. D., Porchia, M., & Santini, C. (2021) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2021.214088 · Cited by 250 · see citing works
New therapeutic strategies for the treatment of acute lymphoblastic leukaemia
Pui, C., & Jeha, S. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2240 · Cited by 234 · see citing works
The role of multidrug resistance efflux transporters in antifolate resistance and folate homeostasis
Assaraf, Y. G. (2006) · Drug Resistance Updates · doi:10.1016/j.drup.2006.09.001 · Cited by 233 · see citing works
Resistance to Chemotherapy in Cancer: A Complex and Integrated Cellular Response
Mellor, H. R., & Callaghan, R. (2008) · Pharmacology · doi:10.1159/000115967 · Cited by 169 · see citing works
Folate receptor β as a potential delivery route for novel folate antagonists to macrophages in the synovial tissue of rheumatoid arthritis patients
van der Heijden, J. W., Oerlemans, R., Dijkmans, B. A. C., Qi, H., van der Laken, C. J., Lems, W. F., Jackman, A. L., Kraan, M. C., Tak, P. P., Ratnam, M., et al. (2008) · Arthritis & Rheumatism · doi:10.1002/art.24219 · Cited by 157 · see citing works
Hyperglycemia Associated Metabolic and Molecular Alterations in Cancer Risk, Progression, Treatment, and Mortality
Ramteke, P. L., Deb, A., Shepal, V., & Bhat, M. K. (2019) · Cancers · doi:10.3390/cancers11091402 · Cited by 156 · see citing works
Molecular mechanism of action and pharmacokinetic properties of methotrexate
Maksimović, V., Pavlović-Popović, Z., Vukmirović, S., Cvejić, J., Mooranian, A., Al‐Salami, H., Mikov, M., & Goločorbin-Kon, S. (2020) · Molecular Biology Reports · doi:10.1007/s11033-020-05481-9 · Cited by 148 · see citing works
Miniature multi-channel SPR instrument for methotrexate monitoring in clinical samples
Zhao, S. S., Bukar, N., Toulouse, J. L., Pelechacz, D., Robitaille, R., Pelletier, J. N., & Masson, J. (2014) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2014.09.082 · Cited by 138 · see citing works
The Folate Pathway Inhibitor Pemetrexed Pleiotropically Enhances Effects of Cancer Immunotherapy
Schaer, D. A., Geeganage, S., Amaladas, N., Lu, Z. H., Rasmussen, E. R., Sonyi, A., Chin, D., Capen, A., Li, Y., Meyer, C. M., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0433 · Cited by 132 · see citing works
Reprogramming of serine, glycine and one-carbon metabolism in cancer
Li, A. M., & Ye, J. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2020.165841 · Cited by 127 · see citing works
Efficacy and Safety of Two Doses of Pemetrexed Supplemented with Folic Acid and Vitamin B12 in Previously Treated Patients with Non-Small Cell Lung Cancer
Ohe, Y., Ichinose, Y., Nakagawa, K., Tamura, T., Kubota, K., Yamamoto, N., Adachi, S., Nambu, Y., Fujimoto, T., Nishiwaki, Y., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5143 · Cited by 120 · see citing works
Organ-Specific Cancer Metabolism and Its Potential for Therapy
Elia, I., Schmieder, R., Christen, S., & Fendt, S. (2015) · Handbook of experimental pharmacology · doi:10.1007/164_2015_10 · Cited by 111 · see citing works
Thymidylate synthase and dihydrofolate reductase expression in non-small cell lung carcinoma: The association with treatment efficacy of pemetrexed
Chen, C., Chang, Y., Shih, J., Lin, J., Chen, K., Yang, C.-H., Yu, C., & Yang, P. (2011) · Lung Cancer · doi:10.1016/j.lungcan.2011.01.024 · Cited by 113 · see citing works
Biosensors and nanobiosensors for therapeutic drug and response monitoring
McKeating, K. S., Aubé, A., & Masson, J. (2015) · The Analyst · doi:10.1039/c5an01861g · Cited by 107 · see citing works
Pharmacological targeting of MTHFD2 suppresses acute myeloid leukemia by inducing thymidine depletion and replication stress
Bonagas, N., Gustafsson, N., Henriksson, M., Marttila, P., Gustafsson, R., Wiita, E., Borhade, S. R., Green, A. C., Vallin, K. S. A., Sarno, A., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00331-y · Cited by 101 · see citing works
Organic Anion Transporting Polypeptides: Emerging Roles in Cancer Pharmacology
Schulte, R. R., & Ho, R. H. (2019) · Molecular Pharmacology · doi:10.1124/mol.118.114314 · Cited by 92 · see citing works
The Intersection of Purine and Mitochondrial Metabolism in Cancer
Vitto, H. D., Arachchige, D., Richardson, B. C., & French, J. B. (2021) · Cells · doi:10.3390/cells10102603 · Cited by 88 · see citing works
Methionine synthase supports tumour tetrahydrofolate pools
Ghergurovich, J. M., Xu, X., Wang, J. Z., Yang, L., Ryseck, R.-P., Wang, L., & Rabinowitz, J. D. (2021) · Nature Metabolism · doi:10.1038/s42255-021-00465-w · Cited by 74 · see citing works
Comparison of pharmacokinetics and toxicity after high-dose methotrexate treatments in children with acute lymphoblastic leukemia
Csordás, K., Hegyi, M., Eipel, O., Müller, J., Erdelyi, D. J., & Kovács, G. (2012) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e32835b8662 · Cited by 73 · see citing works
Dipyridamole prevents triple-negative breast-cancer progression
Spano, D., Marshall, J. –. A., Marino, N., Martino, D. D., Romano, A., Scoppettuolo, M. N., Bello, A. M., Dato, V. D., Navas, L., Vita, G. D., et al. (2012) · Clinical & Experimental Metastasis · doi:10.1007/s10585-012-9506-0 · Cited by 69 · see citing works
Angiogenesis and Metabolism: Entwined for Therapy Resistance
Jiménez-Valerio, G., & Casanovas, O. (2017) · Trends in cancer · doi:10.1016/j.trecan.2016.11.007 · Cited by 68 · see citing works
Methotrexate Normalizes Up‐Regulated Folate Pathway Genes in Rheumatoid Arthritis
Blits, M., Jansen, G., Assaraf, Y. G., van de Wiel, M. A., Lems, W. F., Nurmohamed, M. T., van Schaardenburg, D., Voskuyl, A. E., Wolbink, G., Vosslamber, S., et al. (2013) · Arthritis & Rheumatism · doi:10.1002/art.38094 · Cited by 67 · see citing works
Principles of cytotoxic chemotherapy
Lind, M. (2008) · Medicine · doi:10.1016/j.mpmed.2007.10.003 · Cited by 65 · see citing works
Chapter 4 Molecular Mechanisms of Adaptation to Folate Deficiency
Ifergan, I., & Assaraf, Y. G. (2008) · Vitamins and hormones · doi:10.1016/s0083-6729(08)00404-4 · Cited by 61 · see citing works
Pharmacokinetic Properties of Anticancer Agents for the Treatment of Central Nervous System Tumors: Update of the Literature
Jacus, M. O., Daryani, V. M., Harstead, K. E., Patel, Y. T., Throm, S. L., & Stewart, C. F. (2015) · Clinical Pharmacokinetics · doi:10.1007/s40262-015-0319-6 · Cited by 60 · see citing works
Principles of cytotoxic chemotherapy
Lind, M. (2011) · Medicine · doi:10.1016/j.mpmed.2011.09.009 · Cited by 57 · see citing works
96-Well Plasmonic Sensing with Nanohole Arrays
Couture, M., Ray, K. K., Poirier-Richard, H.-P., Crofton, A., & Masson, J. (2016) · ACS Sensors · doi:10.1021/acssensors.5b00280 · Cited by 55 · see citing works
The Reduced Folate Carrier (RFC) Is Cytotoxic to Cells under Conditions of Severe Folate Deprivation
Ifergan, I., Jansen, G., & Assaraf, Y. G. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m802812200 · Cited by 52 · see citing works
Metformin alleviates memory and hippocampal neurogenesis decline induced by methotrexate chemotherapy in a rat model
Sritawan, N., Prajit, R., Chaisawang, P., Sirichoat, A., Pannangrong, W., Wigmore, P. M., & Welbat, J. U. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110651 · Cited by 51 · see citing works
Resistance Mechanisms in Pediatric B-Cell Acute Lymphoblastic Leukemia
Jędraszek, K., Malczewska, M., Parysek-Wójcik, K., & Lejman, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23063067 · Cited by 52 · see citing works
Targeted metabolomics for serum amino acids and acylcarnitines in patients with lung cancer
Ni, J., Xu, L., Li, W., Zheng, C., & Wu, L. (2019) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2019.7533 · Cited by 48 · see citing works
Folates as adjuvants to anticancer agents: Chemical rationale and mechanism of action
Danenberg, P. V., Gustavsson, B. G., Johnston, P., Lindberg, P., Moser, R., Odin, E., Peters, G. J., & Petrelli, N. J. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.08.001 · Cited by 48 · see citing works
Impact of genetic variants of RFC1, DHFR and MTHFR in osteosarcoma patients treated with high-dose methotrexate
Jabeen, S., Holmboe, L., Alnæs, G. I. G., Andersen, A., Hall, K. S., & Kristensen, V. N. (2015) · The Pharmacogenomics Journal · doi:10.1038/tpj.2015.11 · Cited by 47 · see citing works
Effect of SLCO1B1 Polymorphisms on High‐Dose Methotrexate Clearance in Children and Young Adults With Leukemia and Lymphoblastic Lymphoma
Schulte, R. R., Choi, L., Utreja, N., Driest, S. L. V., Stein, C., & Ho, R. H. (2020) · Clinical and Translational Science · doi:10.1111/cts.12879 · Cited by 44 · see citing works
Historical Perspective and Current Trends in Anticancer Drug Development
Gach, K., Drogosz-Stachowicz, J., Janecka, A. E., Wtorek, K., & Mirowski, M. (2024) · Cancers · doi:10.3390/cancers16101878 · Cited by 43 · see citing works
Associations of novel genetic variations in the folate‐related and ARID 5 B genes with the pharmacokinetics and toxicity of high‐dose methotrexate in paediatric acute lymphoblastic leukaemia
Csordás, K., Lautner‐Csorba, O., Semsei, Á. F., Harnos, A., Hegyi, M., Erdelyi, D. J., Eipel, O., Szalai, C., & Kovács, G. (2014) · British Journal of Haematology · doi:10.1111/bjh.12886 · Cited by 43 · see citing works
The folate metabolic network of Falciparum malaria
Salcedo-Sora, J. E., & Ward, S. A. (2013) · Molecular and Biochemical Parasitology · doi:10.1016/j.molbiopara.2013.02.003 · Cited by 43 · see citing works
Monitoring methotrexate in clinical samples from cancer patients during chemotherapy with a LSPR-based competitive sensor
Zhao, S. S., Bichelberger, M. A., Colin, D. Y., Robitaille, R., Pelletier, J. N., & Masson, J. (2012) · The Analyst · doi:10.1039/c2an35839e · Cited by 42 · see citing works
Cell-penetrating conjugates of pentaglutamylated methotrexate as potential anticancer drugs against resistant tumor cells
Szabó, I., Orbán, E., Schlosser, G., Hudecz, F., & Bánóczi, Z. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.03.034 · Cited by 42 · see citing works
Anti-tumor Study of Chondroitin Sulfate-Methotrexate Nanogels
Wang, J., Zhao, W., Chen, H., Qin, A., & Zhu, P. (2017) · Nanoscale Research Letters · doi:10.1186/s11671-017-2324-1 · Cited by 42 · see citing works
Dihydrofolate Reductase and Thymidylate Synthase Transgenes Resistant to Methotrexate Interact to Permit Novel Transgene Regulation
Rushworth, D., Mathews, A., Alpert, A., & Cooper, L. J. N. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.c115.671123 · Cited by 39 · see citing works
Effect of metformin treatment on memory and hippocampal neurogenesis decline correlated with oxidative stress induced by methotrexate in rats
Sritawan, N., Suwannakot, K., Naewla, S., Chaisawang, P., Aranarochana, A., Sirichoat, A., Pannangrong, W., Wigmore, P. M., & Welbat, J. U. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112280 · Cited by 38 · see citing works
Les antimétabolites
Lansiaux, A. (2011) · Bulletin du Cancer · doi:10.1684/bdc.2011.1476 · Cited by 38 · see citing works
Human constitutive androstane receptor mediated methotrexate induction of human dehydroepiandrosterone sulfotransferase (hSULT2A1)
Chen, X., Zhang, J., Baker, S. M., & Chen, G. (2006) · Toxicology · doi:10.1016/j.tox.2006.12.019 · Cited by 36 · see citing works
One-Carbon Metabolism: Biological Players in Epithelial Ovarian Cancer
Rizzo, A., Napoli, A., Roggiani, F., Tomassetti, A., Bagnoli, M., & Mezzanzanica, D. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19072092 · Cited by 35 · see citing works
Preparation and characterization of nanoparticulate poly( N ‐isopropylacryl‐ amide) hydrogel for the controlled release of anti‐tumour drugs
Blanco, M. D., Guerrero, S., Teijón, C., Olmo, R., Pastrana, L. M., Katime, I., & Teijón, J. M. (2008) · Polymer International · doi:10.1002/pi.2457 · Cited by 35 · see citing works
Methotrexate-induced Hepatic and Renal Toxicity: Role of L-carnitine in Treatment
Tousson, E., Zaki, Z. T., Abu-Shaeir, W. A., & Hassan, H. M. (2014) · Biomedicine and Biotechnology · doi:10.12691/bb-2-4-4 · Cited by 34 · see citing works
Synthesis, Cytotoxic, and Antibacterial Evaluation of Quinazolinone Derivatives with Substituted Amino Moiety
Zhan, X., Xu, Y. P., Qi, Q., Wang, Y., Shi, H., & Mao, Z. (2018) · Chemistry & Biodiversity · doi:10.1002/cbdv.201700513 · Cited by 31 · see citing works
Local chemotherapeutic agents for the treatment of ocular malignancies
Fernandes, B. F., Nikolitch, K., Coates, J. T. T., Novais, G. A., Odashiro, A. N., Odashiro, P. R., Belfort, R. N., & Burnier, M. N. (2013) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2013.01.003 · Cited by 31 · see citing works
Mechanisms of action of FdUMP[10]: Metabolite activation and thymidylate synthase inhibition
Bijnsdorp, I. V., Comijn, E. M., Padrón, J. M., Gmeiner, W. H., & Peters, G. J. (2007) · Oncology Reports · doi:10.3892/or.18.1.287 · Cited by 30 · see citing works
Abrogation by Ginkgo Byloba Leaf Extract on Hepatic and Renal Toxicity Induced by Methotrexate in Rats
Tousson, E., Atteya, Z., El‐Atrash, A., & Jeweely, O. I. (2014) · The Journal of Cancer Research · doi:10.12691/jcrt-2-3-1 · Cited by 30 · see citing works
Design, synthesis and antitumor evaluation of novel pyrazolo[3,4- d ]pyrimidines incorporating different amino acid conjugates as potential DHFR inhibitors
Salem, I. M., Mostafa, S. M., Salama, I., El‐Sabbagh, O. I., Hegazy, W. A. H., & Ibrahim, T. S. (2022) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2022.2142786 · Cited by 28 · see citing works
Methotrexate induces apoptosis in CaSki and NRK cells and influences the organization of their actin cytoskeleton
Mazur, A. J., Nowak, D., Mannherz, H. G., & Malicka-Błaszkiewicz, M. (2009) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.04.020 · Cited by 28 · see citing works
Novel pyrimidopyrimidine derivatives for inhibition of cellular proliferation and motility induced by h-prune in breast cancer
Virgilio, A., Spano, D., Esposito, V., Dato, V. D., Citarella, G., Marino, N., Maffia, V., Martino, D. D., Antonellis, P. D., Galeone, A., et al. (2012) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2012.08.020 · Cited by 27 · see citing works
Naked-eye nanobiosensor for therapeutic drug monitoring of methotrexate
Yockell-Lelièvre, H., Bukar, N., Toulouse, J. L., Pelletier, J. N., & Masson, J. (2015) · The Analyst · doi:10.1039/c5an00996k · Cited by 26 · see citing works
Adverse Effects of Immunosuppression: Infections
Handley, G. H., & Hand, J. M. (2021) · Handbook of experimental pharmacology · doi:10.1007/164_2021_550 · Cited by 25 · see citing works
Dynamics of antifolate transport via the reduced folate carrier and the membrane folate receptor in murine leukaemia cells in vitro and in vivo
Mauritz, R., Peters, G. J., Kathmann, I., Teshale, H., Noordhuis, P., Comijn, E. M., Pinedo, H. M., & Jansen, G. (2008) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-008-0683-0 · Cited by 25 · see citing works
Methotrexate exerts antitumor immune activity and improves the clinical efficacy of immunotherapy in patients with solid tumors
Yang, R., Bei, W., Su, Z., Song, Y., Zhang, Y., Liu, Y., Zhang, Y., He, C., Xi, Y., Zhong, F., et al. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.adn6921 · Cited by 24 · see citing works
RNA interference screening for the discovery of oncology targets
Quon, K. C., & Kassner, P. D. (2009) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728220903179338 · Cited by 24 · see citing works
One-Carbon Metabolism Associated Vulnerabilities in Glioblastoma: A Review
Ghannad‐Zadeh, K., & Das, S. (2021) · Cancers · doi:10.3390/cancers13123067 · Cited by 23 · see citing works
New developments in first- and second-line chemotherapy for transitional cell, squamous cell and adenocarcinoma of the bladder
Santis, M. D., & Bachner, M. (2007) · Current Opinion in Urology · doi:10.1097/mou.0b013e3282c4b0cb · Cited by 23 · see citing works
Substrate channeling between the human dihydrofolate reductase and thymidylate synthase
Wang, N., & McCammon, J. A. (2015) · Protein Science · doi:10.1002/pro.2720 · Cited by 23 · see citing works
Synthesis and evaluation of a classical 2,4-diamino-5-substituted-furo[2,3-d]pyrimidine and a 2-amino-4-oxo-6-substituted-pyrrolo[2,3-d]pyrimidine as antifolates
Gangjee, A., Yang, J., McGuire, J. J., & Kisliuk, R. L. (2006) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2006.08.029 · Cited by 23 · see citing works
Methotrexate resistance and its regulatory mechanisms in pediatric tumors and beyond
Nie, J., Huang, L., Shen, Y., Pan, H., Wang, S., Zhao, H., Gao, P., Yang, J., Huang, X., Zeng, S., et al. (2025) · Drug Resistance Updates · doi:10.1016/j.drup.2025.101225 · Cited by 22 · see citing works
Effects of metabolic cancer therapy on tumor microenvironment
Hyroššová, P., Milošević, M., Škoda, J., Vachtenheim, J., Jr., Rohlena, J., & Rohlenová, K. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1046630 · Cited by 22 · see citing works
New Therapeutic Strategies in Acute Lymphoblastic Leukemia
Jeha, S. (2008) · Seminars in Hematology · doi:10.1053/j.seminhematol.2008.09.009 · Cited by 21 · see citing works
Methotrexate for topical application in an extemporaneous preparation
Wohlrab, J., Neubert, R. H. H., Michael, J., & Naumann, S. (2015) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.12622 · Cited by 21 · see citing works
Anti-Angiogenic Effect of Orally Available Pemetrexed for Metronomic Chemotherapy
Maharjan, R., Pangeni, R., Jha, S. K., Choi, J. U., Chang, K.-Y., Choi, Y. K., Park, J. W., & Byun, Y. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics11070332 · Cited by 20 · see citing works
Comparison of enteral and parenteral methods of urine alkalinization in patients receiving high-dose methotrexate
Rouch, J. A., Burton, B. L., Dabb, A. A., Brown, V., Seung, A. H., Kinsman, K., & Holdhoff, M. (2015) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155215610914 · Cited by 20 · see citing works
Transient Low-Dose Methotrexate Induces Tolerance to Murine Anti-Thymocyte Globulin and Together They Promote Long-Term Allograft Survival
Joseph, A. M., Neff, K. S., Richard, J., Gao, L., Bangari, D. S., Joly, M., Culm-Merdek, K., Garman, R. D., Williams, J. M., Richards, S. M., et al. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1103601 · Cited by 20 · see citing works
Folic Acid, Folate Conjugates and Folate Receptors: Novel Applications in Imaging of Cancer and Inflammation-Related Conditions
Chegeni, N., Kadivar, F., & Saraei, P. (2025) · Cancer Management and Research · doi:10.2147/cmar.s549662 · Cited by 19 · see citing works
Forward Chemical Genetics in Yeast for Discovery of Chemical Probes Targeting Metabolism
St.Onge, R., Schlecht, U., Scharfe, C., & Evangelista, M. (2012) · Molecules · doi:10.3390/molecules171113098 · Cited by 19 · see citing works
On the Rational Design of Cooperative Receptors
Ortega, G., Chamorro-García, A., Ricci, F., & Plaxco, K. W. (2023) · Annual Review of Biophysics · doi:10.1146/annurev-biophys-091222-082247 · Cited by 18 · see citing works
Interplay between mTOR and Purine Metabolism Enzymes and Its Relevant Role in Cancer
Allegrini, S., Camici, M., Garcia‐Gil, M., Pesi, R., & Tozzi, M. G. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25126735 · Cited by 17 · see citing works
Understanding serine and glycine metabolism in cancer: a path towards precision medicine to improve patient’s outcomes
Sánchez‐Castillo, A., & Kampen, K. R. (2024) · Discover Oncology · doi:10.1007/s12672-024-01544-6 · Cited by 17 · see citing works
5,10-Methenyltetrahydrofolate synthetase activity is increased in tumors and modifies the efficacy of antipurine LY309887
Field, M. S., Anguera, M. C., Page, R. L., & Stover, P. J. (2008) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2008.11.001 · Cited by 17 · see citing works
Methotrexate induces high level of apoptosis in canine lymphoma/leukemia cell lines
Pawlak, A., Kutkowska, J., Obmińska‐Mrukowicz, B., & Rapak, A. (2017) · Research in Veterinary Science · doi:10.1016/j.rvsc.2017.09.026 · Cited by 17 · see citing works
New pemetrexed‐peptide conjugates: synthesis, characterization and in vitro cytostatic effect on non‐small cell lung carcinoma (NCI‐H358) and human leukemia (HL‐60) cells
Miklán, Z., Orbán, E., Bánóczi, Z., & Hudecz, F. (2011) · Journal of Peptide Science · doi:10.1002/psc.1407 · Cited by 17 · see citing works
Development and Binding Mode Assessment of N-[4-[2-Propyn-1-yl[(6S)-4,6,7,8-tetrahydro-2-(hydroxymethyl)-4-oxo-3H-cyclopenta[g]quinazolin-6-yl]amino]benzoyl]- l -γ-glutamyl- d -glutamic Acid (BGC 945), a Novel Thymidylate Synthase Inhibitor That Targets Tumor Cells
Tochowicz, A., Dalziel, S. M., Eidam, O., O’Connell, J. D., Griner, S. L., Finer-Moore, J. S., & Stroud, R. M. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400490e · Cited by 17 · see citing works
Genetic variants in one‐carbon metabolism‐related genes contribute to NSCLC prognosis in a Chinese population
Jin, G., Huang, J., Hu, Z., Dai, J., Tang, R., Chen, Y., Xu, L., Huang, X., Shu, Y., & Shen, H. (2010) · Cancer · doi:10.1002/cncr.25301 · Cited by 17 · see citing works
A mathematical model of microbial folate biosynthesis and utilisation: implications for antifolate development
Salcedo-Sora, J. E., & Auley, M. T. M. (2016) · Molecular BioSystems · doi:10.1039/c5mb00801h · Cited by 16 · see citing works
Nucleoside Transport Inhibitors: Structure−Activity Relationships for Pyrimido[5,4-d]pyrimidine Derivatives That Potentiate Pemetrexed Cytotoxicity in the Presence of α1-Acid Glycoprotein
Saravanan, K., Barlow, H. C., Barton, M., Calvert, H., Golding, B. T., Newell, D. R., Northen, J. S., Curtin, N. J., Thomas, H. D., & Griffin, R. J. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm101493z · Cited by 16 · see citing works
2-Tier Bacterial and In Vitro Selection of Active and Methotrexate-Resistant Variants of Human Dihydrofolate Reductase
Fossati, E., Volpato, J. P., Poulin, L., Guerrero, V., Dugas, D.-A., & Pelletier, J. N. (2008) · SLAS DISCOVERY · doi:10.1177/1087057108318783 · Cited by 16 · see citing works
1NM-PP1 Treatment of Mice Infected with Toxoplasma gondii
Sugi, T., Kato, K., Kobayashi, K., Kurokawa, H., Takemae, H., Gong, H., Recuenco, F. C., Iwanaga, T., Horimoto, T., & Akashi, H. (2011) · Journal of Veterinary Medical Science · doi:10.1292/jvms.11-0085 · Cited by 15 · see citing works
Human dihydrofolate reductase inhibition effect of 1-Phenylpyrazolo[3,4–d]pyrimidines: Synthesis, antitumor evaluation and molecular modeling study
Salem, I. M., Mostafa, S. M., Salama, I., El‐Sabbagh, O. I., Hegazy, W. A. H., & Ibrahim, T. S. (2022) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2022.106207 · Cited by 14 · see citing works
Rat liver folate metabolism can provide an independent functioning of associated metabolic pathways
Zaitsev, A. V., Martinov, M. V., Vitvitsky, V., & Иноятович, А. Ф. (2019) · Scientific Reports · doi:10.1038/s41598-019-44009-5 · Cited by 14 · see citing works
Influence of Methylenetetrahydrofolate Reductase C677T and A1298C Polymorphism on High-Dose Methotrexate-Related Toxicities in Pediatric Non-Hodgkin Lymphoma Patients
Lü, S., Zhu, X., Li, W., Chen, H., Zhou, D., Zhen, Z., Sun, F., Huang, J., Zhu, J., Wang, J., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.598226 · Cited by 14 · see citing works
Pemetrexed, a multitargeted antifolate drug, demonstrates lower efficacy in comparison to methotrexate against osteosarcoma cell lines
Bodmer, N., Walters, D. K., & Fuchs, B. (2007) · Pediatric Blood & Cancer · doi:10.1002/pbc.21236 · Cited by 14 · see citing works
Novel insights in folate receptors and transporters: implications for disease and treatment of immune diseases and cancer
Jansen, G., & Peters, G. J. (2015) · Pteridines · doi:10.1515/pterid-2015-0005 · Cited by 14 · see citing works
A folylpoly-γ-glutamate synthase single nucleotide polymorphism associated with response to pemetrexed treatment combined with platinum for non-small cell lung cancer
Fukuda, S., Oguri, T., Kunii, E., Sone, K., Uemura, T., Takakuwa, O., Maeno, K., Kanemitsu, Y., Ohkubo, H., Takemura, M., et al. (2016) · Lung Cancer · doi:10.1016/j.lungcan.2016.10.006 · Cited by 14 · see citing works
Efficient Enrichment of Gene-Modified Primary T Cells via CCR5-Targeted Integration of Mutant Dihydrofolate Reductase
Paul, B., Ibarra, G. S. R., Hubbard, N., Einhaus, T., Astrakhan, A., Rawlings, D. J., Kiem, H., & Peterson, C. W. (2018) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2018.04.002 · Cited by 14 · see citing works
GSEA-assisted gene signatures valid for combinations of prognostic markers in PCNSL
Takashima, Y., Hamano, M., Fukai, J., Iwadate, Y., Kajiwara, K., Kobayashi, T., Hondoh, H., & Yamanaka, R. (2020) · Scientific Reports · doi:10.1038/s41598-020-65463-6 · Cited by 14 · see citing works

Authors: Walling, J.
Affiliations: University of Bristol (GB)
Corresponding author: Walling, Jackie
ORCID: Walling, Jackie
Venue: Investigational New Drugs
Publisher: Springer Science and Business Media LLC
Published: 2006-01
Volume: 24
Issue: 1
Pages: 37-77
ISSN: 0167-6997 (ISSN-L)
1573-0646
DOI: 10.1007/s10637-005-4541-1
OpenAlex: W1993777583
Cited by: 182
References: 353
Citations by year: 2026: 4 · 2025: 7 · 2024: 9 · 2023: 4 · 2022: 11 · 2021: 15 · 2020: 12 · 2019: 10 · 2018: 7 · 2017: 7 · 2016: 8 · 2015: 17 · 2014: 9 · 2013: 7 · 2012: 8
FWCI: 1.55
Type: journal article
Language: en
Open access: closed
Licence: www.springernature.com/gp/researchers/text-and-data-mining (tdm)
www.springernature.com/gp/researchers/text-and-data-mining (vor)
Locations: Investigational New Drugs (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Rheumatology › Folate and B Vitamins Research
Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
Keywords: antifolate, methotrexate, pemetrexed, pharmacodynamics, clinical properties
MeSH terms: Pemetrexed, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Biological Transport, Folic Acid Antagonists, Glutamates, Guanine, Humans, Methotrexate, Neoplasms, Randomized Controlled Trials as Topic, Clinical Trials, Phase II as Topic, Clinical Trials, Phase III as Topic, Drug Resistance, Neoplasm

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

From methotrexate to pemetrexed and beyond. A review of the pharmacodynamic and clinical properties of antifolates

Integrity signals

Claims the paper makes

Claims other papers make about this one

Cites

Cited by

Related

Record

About these checks